Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals Limited reported strong full-year FY26 standalone PAT of ₹167.77 million, up 63% from ₹102.83 million in FY25. Standalone revenue was flat at ₹1,242.69 million vs ₹1,202.69 million. However, consolidated FY26 revenue surged to ₹3,509.93 million from ₹1,631.00 million in FY25, reflecting significant expansion driven by acquisitions including Revat Laboratories, Sai Parenterals Pte. Limited, and SP Analytics (75%). The company completed acquisition of 74.64% stake in Noumed Life Sciences (UK) for AUD 22 million. The company filed its DRHP for a proposed IPO and is awaiting listing. Auditors R Kabra & Co. LLP issued an unmodified opinion on both standalone and consolidated results with no qualifications.
The 63% PAT growth on standalone and 115% revenue growth on consolidated basis signals strong operational performance, though investors should note the revenue growth is heavily acquisition-driven. The upcoming IPO could provide listing liquidity to existing shareholders.